Semaglutides improve heart health by 20% beyond weight loss
The Guardian — May 15, 2024, 11:00 AM UTC
Summary: Semaglutides, found in drugs like Ozempic and Wegovy, show promise in treating obesity beyond diabetes. A new study reveals they improve heart health by 20% regardless of weight loss. This could lead to a shift in how these drugs are viewed and prescribed. Availability challenges, such as NHS guidelines limiting prescriptions, need addressing to combat obesity's rising costs. Exciting developments in weight-loss drugs offer hope for effective obesity management.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.